Key facts
- FOCUSIGHT’s last known valuation is $4.8M (Jan 2023).
- It has raised $1.4M; the latest was Early Stage VC in Dec 2025.
- Notable investors include Marathon Venture Partners, Fong Capital Partners, Fosun Health Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for FOCUSIGHT
- ·The full record, as it builds
Funding rounds
No funding rounds for FOCUSIGHT are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FOCUSIGHT
Operator of an ophthalmology diagnosis and treatment platform intended for hospitals, eye-care clinics, and research institutions. The company delivers ophthalmology treatment solutions featuring brain-science-driven intervention models, wearable intelligent devices, and proprietary technology platforms for visual health, providing patients with an improved quality of ophthalmic treatment.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
FOCUSIGHT doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FOCUSIGHT shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FOCUSIGHT in its N-PORT filings yet. We sweep new filings monthly.